相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: a meta-analysis
Zhiguo Zhang et al.
JOURNAL OF THORACIC DISEASE (2019)
Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib
Mandy R. Sakamoto et al.
CLINICAL LUNG CANCER (2019)
Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma
Aniko Maraz et al.
BMC CANCER (2018)
Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma
Jacques Raphael et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)
Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour
Weili Yang et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2018)
Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M–Mutant Leptomeningeal Lung Adenocarcinoma
Christine Cordova et al.
Journal of Thoracic Oncology (2017)
Brigatinib Activity in Patients with ALK plus NSCLC and Intracranial CNS Metastases in Two Clinical Trials
Scott Gettinger et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study
Jun-Te Hsu et al.
ONCOTARGET (2017)
Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib
Justin F. Gainor et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
分享论文
